Pharmacy Times

JULY 16, 2025

14,15 Lung Cancer Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post Progression Tarlatamab has shown promising efficacy in relapsed SCLC based on the initial single-arm trial findings, leading to an FDA approval in 2024, but challenges with administration have limited its widespread adoption.

HIV Treatment and Prevention Agents 65

HIV Treatment and Prevention Agents Compounding Pharmacies Immunization Chemotherapy 65

Pharmacy Times

JULY 2, 2025

The FDA has approved vancomycin injection, USP (Tyzavan; Hikma Pharmaceuticals PLC), for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections in adult and pediatric patients 1 month and older for whom appropriate dosing can be achieved.

FDA 73

FDA Compounding Pharmacies Compounding Hospitals 73

Pharmacy Times

JULY 14, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Independent Pharmacies 129

Independent Pharmacies Compounding Pharmacies Patient Care Hospitals 129

Pharmacy Times

JULY 22, 2025

Historically, the FDA has required preclinical testing in animals to obtain safety and efficacy data for investigational new drugs (INDs) before they can begin clinical testing in humans. 3 More simply, the FDA is moving preclinical testing from in vivo animal models to in silico and in vitro methods.

FDA 50

FDA Compounding Immunization Compounding Pharmacies 50

Pharmacy Times

JUNE 20, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies 73

Compounding Pharmacies Immunization Specialty Pharmacies Compounding 73

Pharmacy Times

JULY 22, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Mail-Order Pharmacies 50

Mail-Order Pharmacies Community Pharmacies Compounding Pharmacies Immunization 50

Pharmacy Times

JULY 23, 2025

As this market surges toward unprecedented growth over the next decade, specialty pharmacies are increasingly turning to automation to meet demand and manage costs. Specialty pharmacies that prioritize efficiency over empathy risk missing what matters most: Meaningful connection during a critical moment in care.

Specialty Pharmacies 50

Specialty Pharmacies Compounding Pharmacies Immunization Compounding 50

Pharmacy Times

JUNE 24, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies 123

Compounding Pharmacies Immunization Hospitals Compounding 123

Pharmacy Times

JUNE 27, 2025

SHOW MORE The FDA approved acalabrutinib as a frontline option for untreated mantle cell lymphoma. The phase 3 ECHO trial showed significant progression-free survival improvement with acalabrutinib, supporting its approval as a new standard of care for untreated MCL.

FDA 56

FDA Compounding Pharmacies Immunization Chemotherapy 56

Pharmacy Times

JUNE 9, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Chemotherapy 65

Chemotherapy Compounding Pharmacies Immunization Compounding 65

Pharmacy Times

JULY 21, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Vaccines 117

Vaccines Immunization Hospitals Compounding Pharmacies 117

Pharmacy Times

JUNE 30, 2025

SHOW MORE FDA removes REMS for CAR T-cell therapies, enhancing patient access while ensuring safety in cancer treatment. 1 Image Credit: ® Clayton - stock.adobe.com “The FDA has taken the bold step to remove the Risk Evaluation and Mitigation Strategy requirement from giving CAR T therapies.

FDA 100

FDA Compounding Pharmacies Immunization Hospitals 100

Pharmacy Times

JUNE 11, 2025

Klein, MD, FRCP (C), FACC, FAHA, FASE, FESC, director at Pericardial Disease Center and professor of medicine, and Sean Krohn, PharmD, CSP, MSCS, lead clinical pharmacist, specialty pharmacy, discussed a complex case of severe pericarditis in an elderly patient who could not tolerate traditional treatments like NSAIDs or colchicine.

Specialty Pharmacies 65

Specialty Pharmacies Hospitals Compounding Pharmacies FDA 65

Pharmacy Times

JULY 24, 2025

Looking Ahead: Finerenone and Future Recommendations As pharmacists await FDA approval of finerenone, many are already evaluating how this new agent might influence prescribing habits. That’s the key to titrating them to the target doses, promoting long-term medication adherence, and then monitoring for [adverse] effects,” Shah said.

HIV Treatment and Prevention Agents 117

HIV Treatment and Prevention Agents Specialty Pharmacies Compounding Pharmacies Hospitals 117

Pharmacy Times

JUNE 4, 2025

Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!

Compounding Pharmacies 65

Compounding Pharmacies Compounding Immunization Specialty Pharmacies 65

Pharmacy Times

JUNE 9, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies 73

Compounding Pharmacies Hospitals Immunization Chemotherapy 73

Pharmacy Times

JUNE 16, 2025

Nemolizumab targets IL-31 receptor alpha, inhibiting itch and inflammation, and is FDA-approved for use with topical therapies in patients 12 and older. Nemolizumab also received FDA approval in August 2024 as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis.

Compounding Pharmacies 65

Compounding Pharmacies FDA Immunization Mayo Clinic 65

Pharmacy Times

JULY 21, 2025

Transformative advances in continuous glucose monitoring and the impact of FDA over-thecounter approval on diabetes care. As accessible health care providers, pharmacists can educate patients on how to best use these devices, empowering them to take charge of their own health care. REFERENCES Afridi Z, Rauf SA, Ashraf SMN, Haque MA.

Compounding Pharmacies 65

Compounding Pharmacies Immunization Insurance Coverage Hospitals 65

Pharmacy Times

JUNE 12, 2025

Related Videos Related Content Advertisement June 12th 2025 Mitomycin Intravesical Solution Receives FDA Approval for Non-Muscle Invasive Bladder Cancer Alexandra Gerlach, Associate Editor June 3rd 2025 S2. Subscribe Now!

Compounding Pharmacies 113

Compounding Pharmacies Vaccines Immunization Specialty Pharmacies 113

Pharmacy Times

JULY 12, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Independent Pharmacies 65

Independent Pharmacies Hospitals Compounding Pharmacies Immunization 65

Pharmacy Times

JUNE 19, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies 65

Compounding Pharmacies Immunization Compounding Hospitals 65

Pharmacy Times

JUNE 20, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies 65

Compounding Pharmacies Hospitals Immunization Compounding 65

Pharmacy Times

JUNE 18, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Immunization 65

Immunization Compounding Pharmacies Hospitals Chemotherapy 65

Pharmacy Times

JULY 18, 2025

Updated March 28, 2025. Accessed June 6, 2025. Take Back Day. United States Drug Enforcement Administration. Accessed June 6, 2025. Drug disposal: drug take-back options. Updated October 31, 2024. Accessed June 6, 2025.

HIV Treatment and Prevention Agents 50

HIV Treatment and Prevention Agents Compounding Compounding Pharmacies Immunization 50

Pharmacy Times

JUNE 13, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies 89

Compounding Pharmacies Immunization Hospitals Vaccines 89

Pharmacy Times

JUNE 25, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Immunization 50

Immunization Compounding Pharmacies Hospitals Compounding 50

Pharmacy Times

JULY 24, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies 65

Compounding Pharmacies Community Pharmacies Vaccines Immunization 65

Pharmacy Times

JUNE 23, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Hospitals 65

Hospitals Compounding Pharmacies Vaccines Immunization 65

Pharmacy Times

JUNE 9, 2025

SHOW MORE The FDA has approved a groundbreaking single-pill combination therapy for hypertension, enhancing cardiovascular health with triple-agent efficacy. The therapy provides a convenient single-pill regimen, potentially benefiting a broad range of patients, including those starting hypertension treatment.

FDA 82

FDA Compounding Pharmacies Immunization Compounding 82

Pharmacy Times

JULY 25, 2025

SHOW MORE Avatrombopag gains FDA approval for pediatric ITP treatment, offering a new oral option for managing chronic thrombocytopenia in children. Common adverse reactions in pediatric patients included viral infections, nasopharyngitis, and cough, but the drug was generally well-tolerated.

Immunization 65

Immunization FDA Mayo Clinic Adverse Reactions 65

Pharmacy Times

JUNE 25, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Vaccines 50

Vaccines Compounding Pharmacies Immunization Specialty Pharmacies 50

Pharmacy Times

JUNE 20, 2025

SHOW MORE The FDA approves dupilumab as the first targeted treatment for bullous pemphigoid, offering hope for patients with this debilitating skin condition. FDA officials approved dupilumab (Dupixent; Sanofi, Regeneron) for the treatment of adults with bullous pemphigoid (BP), marking the first and only targeted treatment for BP.

FDA 82

FDA Compounding Pharmacies Immunization Compounding 82

Pharmacy Times

JULY 8, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies 73

Compounding Pharmacies Immunization Specialty Pharmacies Compounding 73

Pharmacy Times

JULY 19, 2025

A new drug application for lorundrostat is expected to be filed with the FDA in 2025. The most frequent dose limiting adverse effect is hyperkalemia which is dose-related with an incidence of 5% to 7%. mg/d, 1 mg/d, 2 mg/d, and placebo for 12 weeks. 17 The placebo-subtracted reductions in sBP were 8.1 mmHg (p = 0.003) and 11.0

HIV Treatment and Prevention Agents 56

HIV Treatment and Prevention Agents Compounding Pharmacies Vaccines Immunization 56

Pharmacy Times

JULY 16, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies 65

Compounding Pharmacies Hospitals Immunization Specialty Pharmacies 65

Pharmacy Times

JULY 4, 2025

2 There are several FDA-approved adalimumab biosimilars—including interchangeable products—that are available to patients. They are biologic medications that are highly similar to their reference products without having any clinically meaningful differences.

Specialty Pharmacies 86

Specialty Pharmacies Hospitals Compounding Pharmacies Vaccines 86

Pharmacy Times

JUNE 11, 2025

Image Credit: © Chinnapong - stock.adobe.com At the 2025 Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025, an encore presentation from the Pacific Coast Reproductive Society Annual Meeting will highlight findings from a retrospective analysis conducted by Walgreens Specialty Pharmacy.

Specialty Pharmacies 73

Specialty Pharmacies Compounding Pharmacies Immunization Chemotherapy 73